Details for Patent: 7,807,689
✉ Email this page to a colleague
Which drugs does patent 7,807,689 protect, and when does it expire?
Patent 7,807,689 protects KAZANO, NESINA, and OSENI, and is included in three NDAs.
This patent has fifty-eight patent family members in thirty-five countries.
Summary for Patent: 7,807,689
Title: | Dipeptidyl peptidase inhibitors |
Abstract: | The present invention provides a compound of the formula: ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same. |
Inventor(s): | Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Ulysse; Luckner G. (Albany, NY) |
Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
Application Number: | 11/080,992 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,807,689 |
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Dosage form; Delivery; Use; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 7,807,689
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-002 | Jan 25, 2013 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Subscribe | ||
Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-001 | Jan 25, 2013 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Subscribe | ||
Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-001 | Jan 25, 2013 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Subscribe | ||
Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-002 | Jan 25, 2013 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Subscribe | ||
Takeda Pharms Usa | NESINA | alogliptin benzoate | TABLET;ORAL | 022271-003 | Jan 25, 2013 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Subscribe | ||
Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-004 | Jan 25, 2013 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,807,689
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 1586571 | ⤷ Subscribe | C300640 | Netherlands | ⤷ Subscribe |
European Patent Office | 1586571 | ⤷ Subscribe | CA 2014 00011 | Denmark | ⤷ Subscribe |
European Patent Office | 1586571 | ⤷ Subscribe | PA2014011 | Lithuania | ⤷ Subscribe |
European Patent Office | 1586571 | ⤷ Subscribe | 14C0013 | France | ⤷ Subscribe |
European Patent Office | 1586571 | ⤷ Subscribe | 172 5006-2014 | Slovakia | ⤷ Subscribe |
European Patent Office | 1586571 | ⤷ Subscribe | C20140007 00126 | Estonia | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |